MAPK7 and cancer: The multivariate analysis both for recurrence-free rate and cancer-specific survival did not show that ERK5 is an independent prognostic factor (HR [95%CI]; 1.270 [0.616–2.405], 1.099 [0.480–2.514], respectively).